Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...
Involvement of problematic areas -- scalp, intertriginous sites ... does not see as many cases of mild/moderate psoriasis as community dermatologists. Nonetheless, his decision-making regarding ...
Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.
The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...
In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...
"Based on the especially promising safety and efficacy results from patients with mild-to-moderate psoriasis in Cohort 2 of our Phase 1b clinical trial, we are confident that SFA-002 will ...
JENKINTOWN, Pa., March 7, 2025 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic compounds for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results